Guardant Health (GH) introduces IHC Solid Tumor Testing to its Portfolio

On May 21, Guardant Health, Inc. (NASDAQ:GH) announced adding a full suite of immunohistochemistry to its portfolio of tumor molecular profiling tests. This addition will help oncologists identify the subtypes of tumors, thereby enabling them to match cancer patients with targeted therapies.

Analysing a blood sample, a technician in a lab coat using precision diagnostic equipment.

Guardant Health, Inc. (NASDAQ:GH) is a precision oncology company specializing in advanced blood and tissue tests, real-world data, and artificial intelligence analytics. Immunohistochemistry testing, also known as IHC, is a specialized staining technique used to detect specific proteins called tumor biomarkers within tissue samples. These biomarkers reveal important characteristics of a tumor that help doctors determine the most appropriate targeted cancer therapies. The testing suite introduced by Guardant Health, Inc. (NASDAQ:GH) covers various biomarkers, including HER2, MMR, PD-L1, c-MET, ER, PR, Ki-67, CLDN18, and FOLR1.

Helmy Eltoukhy, chairman and co-CEO of the company, said:

“The information about tumor characteristics garnered from advanced IHC testing will complement the multidimensional insights we are currently providing to oncologists through our recently introduced Guardant360 Tissue multi-omic tumor profiling test.”

To put things into perspective, Guardant Health, Inc. (NASDAQ:GH) launched its upgraded version of Guardant360 Tissue, which is the first of its kind multi-omic CGP product with expanded genomic and epigenomic breadth. These are significant developments as Oncology segments contribute more than 50% to the total revenue. During the fiscal first quarter of 2025, the Oncology revenue contributed $150.6 million to the total revenue of $203.5 million, driven by 59,000 oncology tests.

While we acknowledge the potential of GH as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than GH and that has 100x upside potential, check out our report about the cheapest AI stock.

READ NEXT: 11 Most Promising New Technology Stocks According to Analysts and 12 Best Growth Stocks to Buy and Hold for the Long Term.

Disclosure: None